Skip to main content
Erschienen in: Neurotherapeutics 1/2014

01.01.2014 | Review

Treatment of Cognitive, Psychiatric, and Affective Disorders Associated with Parkinson’s Disease

verfasst von: Barbara Connolly, Susan H. Fox

Erschienen in: Neurotherapeutics | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Neuropsychiatric symptoms are common in Parkinson’s disease (PD) and add significantly to the burden of disease. These symptoms are most commonly part of the disease spectrum owing to pathological changes within relevant brain regions. Neuropsychiatric problems include disorders of cognition, ranging from mild cognitive impairment to dementia, psychotic symptoms, including, most commonly, well-formed visual hallucinations and paranoid delusions, and mood disorders, such as depression and anxiety. The other common cause of neuropsychiatric problem is secondary to use of dopaminergic drugs. Some PD patients may develop behavioral disorders, including impulse control disorders (ICDs) and addictive symptoms. Psychosis can be due to a mixture of underlying pathology, with triggering or worsening of symptoms with changes to PD medications. Currently, management of these disorders primarily uses therapies developed for general psychiatry and cognitive neurology, rather than specifically for PD. However, significant adverse effects, such as worsening of the motor symptoms of PD, can limit use of some drug therapies. Identification of drug-induced symptoms, such as ICDs, enables withdrawal of the offending drug as the principal management strategy. Research is ongoing in an effort to develop more specific therapies for PD-related neuropsychiatric symptoms.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Broeders M, De Bie RM, Velseboer DC, Speelman JD, Muslimovic D, Schmand B. Evolution of mild cognitive impairment in Parkinson disease. Neurology 2013;81:346-352.PubMed Broeders M, De Bie RM, Velseboer DC, Speelman JD, Muslimovic D, Schmand B. Evolution of mild cognitive impairment in Parkinson disease. Neurology 2013;81:346-352.PubMed
2.
Zurück zum Zitat Marras C, Armstrong MJ, Meaney CA, et al. Measuring mild cognitive impairment in patients with Parkinson's disease. Mov Disord 2013;28:626-633.PubMed Marras C, Armstrong MJ, Meaney CA, et al. Measuring mild cognitive impairment in patients with Parkinson's disease. Mov Disord 2013;28:626-633.PubMed
3.
Zurück zum Zitat Litvan I, Aarsland D, Adler CH, et al. MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. Mov Disord 2011;26:1814-1824.PubMedCentralPubMed Litvan I, Aarsland D, Adler CH, et al. MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. Mov Disord 2011;26:1814-1824.PubMedCentralPubMed
4.
Zurück zum Zitat Litvan I, Goldman JG, Troster AI, et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord 2012;27:349-356.PubMedCentralPubMed Litvan I, Goldman JG, Troster AI, et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord 2012;27:349-356.PubMedCentralPubMed
5.
Zurück zum Zitat Muslimovic D, Post B, Speelman JD, Schmand B. Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology 2005;65:1239-1245.PubMed Muslimovic D, Post B, Speelman JD, Schmand B. Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology 2005;65:1239-1245.PubMed
6.
Zurück zum Zitat Janvin CC, Larsen JP, Aarsland D, Hugdahl K. Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia. Mov Disord 2006;21:1343-1349.PubMed Janvin CC, Larsen JP, Aarsland D, Hugdahl K. Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia. Mov Disord 2006;21:1343-1349.PubMed
7.
Zurück zum Zitat Williams-Gray CH, Evans JR, Goris A, et al. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain 2009;132:2958-2969.PubMed Williams-Gray CH, Evans JR, Goris A, et al. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain 2009;132:2958-2969.PubMed
8.
Zurück zum Zitat Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007;22:1689-1707.PubMed Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007;22:1689-1707.PubMed
9.
Zurück zum Zitat McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies - Third report of the DLB consortium. Neurology 2005;65:1863-1872.PubMed McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies - Third report of the DLB consortium. Neurology 2005;65:1863-1872.PubMed
10.
Zurück zum Zitat McKeith I, Mintzer J, Aarsland D, et al. Dementia with Lewy bodies. Lancet Neurol 2004;3:19-28.PubMed McKeith I, Mintzer J, Aarsland D, et al. Dementia with Lewy bodies. Lancet Neurol 2004;3:19-28.PubMed
11.
Zurück zum Zitat Leroi I, McDonald K, Pantula H, Harbishettar V. Cognitive impairment in Parkinson disease: impact on quality of life, disability, and caregiver burden. J Geriatr Psychiatry Neurol 2012;25:208-214.PubMed Leroi I, McDonald K, Pantula H, Harbishettar V. Cognitive impairment in Parkinson disease: impact on quality of life, disability, and caregiver burden. J Geriatr Psychiatry Neurol 2012;25:208-214.PubMed
12.
Zurück zum Zitat Weintraub D, Burn DJ. Parkinson's disease: the quintessential neuropsychiatric disorder. Mov Disord 2011;26:1022-1031.PubMedCentralPubMed Weintraub D, Burn DJ. Parkinson's disease: the quintessential neuropsychiatric disorder. Mov Disord 2011;26:1022-1031.PubMedCentralPubMed
13.
Zurück zum Zitat Uc EY, McDermott MP, Marder KS, et al. Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort. Neurology 2009;73:1469-1477.PubMed Uc EY, McDermott MP, Marder KS, et al. Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort. Neurology 2009;73:1469-1477.PubMed
14.
Zurück zum Zitat Jellinger KA. Neurobiology of cognitive impairment in Parkinson's disease. Expert Rev Neurother 2012;12:1451-1466.PubMed Jellinger KA. Neurobiology of cognitive impairment in Parkinson's disease. Expert Rev Neurother 2012;12:1451-1466.PubMed
15.
Zurück zum Zitat Linazasoro G, Lasa A, Van Blercom N. Efficacy and safety of donepezil in the treatment of executive dysfunction in Parkinson disease - A pilot study. Clin Neuropharmacol 2005;28:176-178.PubMed Linazasoro G, Lasa A, Van Blercom N. Efficacy and safety of donepezil in the treatment of executive dysfunction in Parkinson disease - A pilot study. Clin Neuropharmacol 2005;28:176-178.PubMed
16.
Zurück zum Zitat Hanagasi HA, Gurvit H, Unsalan P, et al. The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study. Mov Disord 2011;26:1851-1858.PubMed Hanagasi HA, Gurvit H, Unsalan P, et al. The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study. Mov Disord 2011;26:1851-1858.PubMed
17.
Zurück zum Zitat Marsh L, Biglan K, Gerstenhaber M, Williams JR. Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study. Mov Disord 2009;24:277-282.PubMedCentralPubMed Marsh L, Biglan K, Gerstenhaber M, Williams JR. Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study. Mov Disord 2009;24:277-282.PubMedCentralPubMed
18.
Zurück zum Zitat Weintraub D, Mavandadi S, Mamikonyan E, et al. Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology 2010;75:448-455.PubMed Weintraub D, Mavandadi S, Mamikonyan E, et al. Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology 2010;75:448-455.PubMed
19.
Zurück zum Zitat Auriel E, Hausdorff JM, Herman T, Simon ES, Giladi N. Effects of methylphenidate on cognitive function and gait in patients with Parkinson's disease - A pilot study. Clin Neuropharmacol 2006;29:15-17.PubMed Auriel E, Hausdorff JM, Herman T, Simon ES, Giladi N. Effects of methylphenidate on cognitive function and gait in patients with Parkinson's disease - A pilot study. Clin Neuropharmacol 2006;29:15-17.PubMed
20.
Zurück zum Zitat Espay AJ, Dwivedi AK, Payne M, et al. Methylphenidate for gait impairment in Parkinson disease: a randomized clinical trial. Neurology 2011;76:1256-1262.PubMed Espay AJ, Dwivedi AK, Payne M, et al. Methylphenidate for gait impairment in Parkinson disease: a randomized clinical trial. Neurology 2011;76:1256-1262.PubMed
21.
Zurück zum Zitat Moreau C, Delval A, Defebvre L, et al. Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial. Lancet Neurol 2012;11:589-596.PubMed Moreau C, Delval A, Defebvre L, et al. Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial. Lancet Neurol 2012;11:589-596.PubMed
22.
Zurück zum Zitat Weintraub D, Somogyi M, Meng X. Rivastigmine in Alzheimer's disease and Parkinson's disease dementia: an ADAS-cog factor analysis. Am J Alzheimers Dis Other Demen 2011;26:443-449.PubMed Weintraub D, Somogyi M, Meng X. Rivastigmine in Alzheimer's disease and Parkinson's disease dementia: an ADAS-cog factor analysis. Am J Alzheimers Dis Other Demen 2011;26:443-449.PubMed
23.
Zurück zum Zitat Rolinski M, Fox C, Maidment I, McShane R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database Syst Rev 2012;3:CD006504.PubMed Rolinski M, Fox C, Maidment I, McShane R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database Syst Rev 2012;3:CD006504.PubMed
24.
Zurück zum Zitat Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004;351:2509-2518.PubMed Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004;351:2509-2518.PubMed
25.
Zurück zum Zitat Wesnes KA, McKeith I, Edgar C, Emre M, Lane R. Benefits of rivastigmine on attention in dementia associated with Parkinson disease. Neurology 2005;65:1654-1656.PubMed Wesnes KA, McKeith I, Edgar C, Emre M, Lane R. Benefits of rivastigmine on attention in dementia associated with Parkinson disease. Neurology 2005;65:1654-1656.PubMed
26.
Zurück zum Zitat Schmitt FA, Farlow MR, Meng XY, Tekin S, Olin JT. Efficacy of rivastigmine on executive function in patients with Parkinson's disease dementia. CNS Neurosci Ther 2010;16:330-336.PubMed Schmitt FA, Farlow MR, Meng XY, Tekin S, Olin JT. Efficacy of rivastigmine on executive function in patients with Parkinson's disease dementia. CNS Neurosci Ther 2010;16:330-336.PubMed
27.
Zurück zum Zitat Olin JT, Aarsland D, Meng XY. Rivastigmine in the treatment of dementia associated with Parkinson's disease: effects on activities of daily living. Dement Geriatr Cogn Disord 2010;29:510-515.PubMed Olin JT, Aarsland D, Meng XY. Rivastigmine in the treatment of dementia associated with Parkinson's disease: effects on activities of daily living. Dement Geriatr Cogn Disord 2010;29:510-515.PubMed
28.
Zurück zum Zitat McKeith I, Del ST, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000;356:2031-2036.PubMed McKeith I, Del ST, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000;356:2031-2036.PubMed
29.
Zurück zum Zitat Oertel W, Poewe W, Wolters E, et al. Effects of rivastigmine on tremor and other motor symptoms in patients with Parkinson's disease dementia – a retrospective analysis of a double-blind trial and an open- label extension. Drug Saf 2008;31:79-94.PubMed Oertel W, Poewe W, Wolters E, et al. Effects of rivastigmine on tremor and other motor symptoms in patients with Parkinson's disease dementia – a retrospective analysis of a double-blind trial and an open- label extension. Drug Saf 2008;31:79-94.PubMed
30.
Zurück zum Zitat Sadowsky CH, Farlow MR, Meng X, Olin JT. Safety and tolerability of rivastigmine transdermal patch compared with rivastigmine capsules in patients switched from donepezil: data from three clinical trials. Int J Clin Pract 2010;64:188-193.PubMed Sadowsky CH, Farlow MR, Meng X, Olin JT. Safety and tolerability of rivastigmine transdermal patch compared with rivastigmine capsules in patients switched from donepezil: data from three clinical trials. Int J Clin Pract 2010;64:188-193.PubMed
31.
Zurück zum Zitat Rowan E, McKeith IG, Saxby BK, et al. Effects of donepezil on central processing speed and attentional measures in Parkinson's disease with dementia and dementia with Lewy bodies. Dement Geriatr Cogn Disord 2007;23:161-167.PubMed Rowan E, McKeith IG, Saxby BK, et al. Effects of donepezil on central processing speed and attentional measures in Parkinson's disease with dementia and dementia with Lewy bodies. Dement Geriatr Cogn Disord 2007;23:161-167.PubMed
32.
Zurück zum Zitat Muller T, Welnic J, Fuchs G, Baas H, Ebersbach G, Reichmann H. The DONPAD-study--treatment of dementia in patients with Parkinson's disease with donepezil. J Neural Transm Suppl 2006;27-30. Muller T, Welnic J, Fuchs G, Baas H, Ebersbach G, Reichmann H. The DONPAD-study--treatment of dementia in patients with Parkinson's disease with donepezil. J Neural Transm Suppl 2006;27-30.
33.
Zurück zum Zitat Ravina B, Putt M, Siderowf A, et al. Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry 2005;76:934-939.PubMed Ravina B, Putt M, Siderowf A, et al. Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry 2005;76:934-939.PubMed
34.
Zurück zum Zitat Leroi I, Brandt J, Reich SG, et al. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int J Geriatr Psychiatry 2004;19:1-8.PubMed Leroi I, Brandt J, Reich SG, et al. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int J Geriatr Psychiatry 2004;19:1-8.PubMed
35.
Zurück zum Zitat Aarsland D, Laake K, Larsen JP, Janvin C. Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 2002;72:708-712.PubMed Aarsland D, Laake K, Larsen JP, Janvin C. Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 2002;72:708-712.PubMed
36.
Zurück zum Zitat Dubois B, Tolosa E, Katzenschlager R, et al. Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study. Mov Disord 2012;27:1230-1238.PubMed Dubois B, Tolosa E, Katzenschlager R, et al. Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study. Mov Disord 2012;27:1230-1238.PubMed
37.
Zurück zum Zitat Mori E, Ikeda M, Kosaka K. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. Ann Neurol 2012;72:41-52.PubMed Mori E, Ikeda M, Kosaka K. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. Ann Neurol 2012;72:41-52.PubMed
38.
Zurück zum Zitat Litvinenko I, Odinak MM, Mogilnaya VI, Emelin A. Efficacy and safety of galantamine (Reminyl) in the treatment of dementia in patients with Parkinson's disease (Open-label controlled trial). Z Nevrol Psikhiatrii Im Ss Ko 2007;107:25-33. Litvinenko I, Odinak MM, Mogilnaya VI, Emelin A. Efficacy and safety of galantamine (Reminyl) in the treatment of dementia in patients with Parkinson's disease (Open-label controlled trial). Z Nevrol Psikhiatrii Im Ss Ko 2007;107:25-33.
39.
Zurück zum Zitat Aarsland D, Hutchinson M, Larsen JP. Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. Int J Geriatr Psychiatry 2003;18:937-941.PubMed Aarsland D, Hutchinson M, Larsen JP. Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. Int J Geriatr Psychiatry 2003;18:937-941.PubMed
40.
Zurück zum Zitat Emre M, Tsolaki M, Bonuccelli U, et al. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010;9:969-977.PubMed Emre M, Tsolaki M, Bonuccelli U, et al. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010;9:969-977.PubMed
41.
Zurück zum Zitat Aarsland D, Ballard C, Walker Z, et al. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo- controlled, multicentre trial. Lancet Neurol 2009;8:613-618.PubMed Aarsland D, Ballard C, Walker Z, et al. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo- controlled, multicentre trial. Lancet Neurol 2009;8:613-618.PubMed
42.
Zurück zum Zitat Leroi I, Overshott R, Byrne EJ, Daniel E, Burns A. Randomized controlled trial of memantine in dementia associated with Parkinson's disease. Mov Disord 2009;24:1217-1221PubMed Leroi I, Overshott R, Byrne EJ, Daniel E, Burns A. Randomized controlled trial of memantine in dementia associated with Parkinson's disease. Mov Disord 2009;24:1217-1221PubMed
43.
Zurück zum Zitat Naismith SL, Mowszowski L, Diamond K, Lewis SJ. Improving memory in Parkinson's disease: a healthy brain ageing cognitive training program. Mov Disord 2013;28:1097-1103.PubMed Naismith SL, Mowszowski L, Diamond K, Lewis SJ. Improving memory in Parkinson's disease: a healthy brain ageing cognitive training program. Mov Disord 2013;28:1097-1103.PubMed
44.
Zurück zum Zitat Hindle JV, Petrelli A, Clare L, Kalbe E. Nonpharmacological enhancement of cognitive function in Parkinson's disease: a systematic review. Mov Disord 2013;28:1034-1049.PubMed Hindle JV, Petrelli A, Clare L, Kalbe E. Nonpharmacological enhancement of cognitive function in Parkinson's disease: a systematic review. Mov Disord 2013;28:1034-1049.PubMed
45.
Zurück zum Zitat Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1154-1166. Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1154-1166.
46.
Zurück zum Zitat Hely MA, Morris JGL, Reid WGJ, Trafficante R. Sydney multicenter study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005;20:190-199.PubMed Hely MA, Morris JGL, Reid WGJ, Trafficante R. Sydney multicenter study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005;20:190-199.PubMed
47.
Zurück zum Zitat Fenelon G, Soulas T, Zenasni F, Cleret de LL. The changing face of Parkinson's disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria. Mov Disord 2010;25:763-766. Fenelon G, Soulas T, Zenasni F, Cleret de LL. The changing face of Parkinson's disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria. Mov Disord 2010;25:763-766.
48.
Zurück zum Zitat Friedman JH. Parkinson disease psychosis: update. Behav Neurol 2013;27:469-477.PubMed Friedman JH. Parkinson disease psychosis: update. Behav Neurol 2013;27:469-477.PubMed
49.
Zurück zum Zitat Gomez-Esteban JC, Tijero B, Somme J, et al. Impact of psychiatric symptoms and sleep disorders on the quality of life of patients with Parkinson's disease. J Neurol 2011;258:494-499.PubMed Gomez-Esteban JC, Tijero B, Somme J, et al. Impact of psychiatric symptoms and sleep disorders on the quality of life of patients with Parkinson's disease. J Neurol 2011;258:494-499.PubMed
50.
Zurück zum Zitat Aarsland D, Larsen JP, Tandberg E, Laake K. Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study. J Am Geriatr Soc 2000;48:938-942.PubMed Aarsland D, Larsen JP, Tandberg E, Laake K. Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study. J Am Geriatr Soc 2000;48:938-942.PubMed
51.
Zurück zum Zitat Forsaa EB, Larsen JP, WentzelLarsen T, et al. A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol 2010;67:996-1001.PubMed Forsaa EB, Larsen JP, WentzelLarsen T, et al. A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol 2010;67:996-1001.PubMed
52.
Zurück zum Zitat Aarsland D, Kurz MW. The epidemiology of dementia associated with Parkinson disease. J Neurol Sci 2010;289:18-22.PubMed Aarsland D, Kurz MW. The epidemiology of dementia associated with Parkinson disease. J Neurol Sci 2010;289:18-22.PubMed
53.
Zurück zum Zitat Chopra A, Tye SJ, Lee KH, et al. Underlying neurobiology and clinical correlates of mania status after subthalamic nucleus deep brain stimulation in Parkinson's disease: a review of the literature. J Neuropsychiatry Clin Neurosci 2012;24:102-110.PubMedCentralPubMed Chopra A, Tye SJ, Lee KH, et al. Underlying neurobiology and clinical correlates of mania status after subthalamic nucleus deep brain stimulation in Parkinson's disease: a review of the literature. J Neuropsychiatry Clin Neurosci 2012;24:102-110.PubMedCentralPubMed
54.
Zurück zum Zitat Schilbach L, Weiss PH, Kuhn J, Timmermann L, Klosterkotter J, Huff W. Pharmacological treatment of deep brain stimulation-induced hypomania leads to clinical remission while preserving motor benefits. Neurocase 2012;18:152-159.PubMed Schilbach L, Weiss PH, Kuhn J, Timmermann L, Klosterkotter J, Huff W. Pharmacological treatment of deep brain stimulation-induced hypomania leads to clinical remission while preserving motor benefits. Neurocase 2012;18:152-159.PubMed
55.
Zurück zum Zitat Allen P, Laroi F, McGuire PK, Aleman A. The hallucinating brain: a review of structural and functional neuroimaging studies of hallucinations. Neurosci Biobehav Rev 2008;32:175-191.PubMed Allen P, Laroi F, McGuire PK, Aleman A. The hallucinating brain: a review of structural and functional neuroimaging studies of hallucinations. Neurosci Biobehav Rev 2008;32:175-191.PubMed
56.
Zurück zum Zitat Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 2002;125:391-403.PubMed Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 2002;125:391-403.PubMed
57.
Zurück zum Zitat Kalaitzakis ME, Christian LM, Moran LB, Graeber MB, Pearce RKB, Gentleman SM. Dementia and visual hallucinations associated with limbic pathology in Parkinson's disease. Parkinsonism Relat Disord 2009;15:196-204.PubMed Kalaitzakis ME, Christian LM, Moran LB, Graeber MB, Pearce RKB, Gentleman SM. Dementia and visual hallucinations associated with limbic pathology in Parkinson's disease. Parkinsonism Relat Disord 2009;15:196-204.PubMed
58.
Zurück zum Zitat Boecker H, CeballosBaumann AO, Volk D, Conrad B, Forstl H, Haussermann P. Metabolic alterations in patients with Parkinson disease and visual hallucinations. Arch Neurol 2007;64:984-988.PubMed Boecker H, CeballosBaumann AO, Volk D, Conrad B, Forstl H, Haussermann P. Metabolic alterations in patients with Parkinson disease and visual hallucinations. Arch Neurol 2007;64:984-988.PubMed
59.
Zurück zum Zitat Meppelink AM, de Jong BM, Renken R, Leenders KL, Cornelissen FW, van Laar T. Impaired visual processing preceding image recognition in Parkinson's disease patients with visual hallucinations. Brain 2009;132:2980-2993.PubMed Meppelink AM, de Jong BM, Renken R, Leenders KL, Cornelissen FW, van Laar T. Impaired visual processing preceding image recognition in Parkinson's disease patients with visual hallucinations. Brain 2009;132:2980-2993.PubMed
60.
Zurück zum Zitat Ballanger B, Strafella AP, van Eimeren T, et al. Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch Neurol 2010;67:416-421.PubMed Ballanger B, Strafella AP, van Eimeren T, et al. Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch Neurol 2010;67:416-421.PubMed
61.
Zurück zum Zitat Goldman JG, Vaughan CL, Goetz CG. An update expert opinion on management and research strategies in Parkinson's disease psychosis. Expert Opin Pharmacother 2011;12:2009-2024.PubMedCentralPubMed Goldman JG, Vaughan CL, Goetz CG. An update expert opinion on management and research strategies in Parkinson's disease psychosis. Expert Opin Pharmacother 2011;12:2009-2024.PubMedCentralPubMed
62.
Zurück zum Zitat Ford B, Lynch T, Greene P. Risperidone in Parkinson's disease. Lancet 1994 ;344:681.PubMed Ford B, Lynch T, Greene P. Risperidone in Parkinson's disease. Lancet 1994 ;344:681.PubMed
63.
Zurück zum Zitat Factor SA, Molho ES, Friedman JH. Risperidone and Parkinson's disease. Mov Disord 2002;17:221-222.PubMed Factor SA, Molho ES, Friedman JH. Risperidone and Parkinson's disease. Mov Disord 2002;17:221-222.PubMed
64.
Zurück zum Zitat Breier A, Sutton VK, Feldman PD, et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease. Biol Psychiatry 2002;52:438-445.PubMed Breier A, Sutton VK, Feldman PD, et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease. Biol Psychiatry 2002;52:438-445.PubMed
65.
Zurück zum Zitat Ondo WG, Levy JK, Vuong KD, Hunter C, Jankovic J. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord 2002;17:1031-1035.PubMed Ondo WG, Levy JK, Vuong KD, Hunter C, Jankovic J. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord 2002;17:1031-1035.PubMed
66.
Zurück zum Zitat Pintor L, Valldeoriola F, Bailles E, Marti MJ, Muniz A, Tolosa E. Ziprasidone versus clozapine in the treatment of psychotic symptoms in Parkinson disease: a randomized open clinical trial. Clin Neuropharmacol 2012;35:61-66.PubMed Pintor L, Valldeoriola F, Bailles E, Marti MJ, Muniz A, Tolosa E. Ziprasidone versus clozapine in the treatment of psychotic symptoms in Parkinson disease: a randomized open clinical trial. Clin Neuropharmacol 2012;35:61-66.PubMed
67.
Zurück zum Zitat Schindehutte J, Trenkwalder C. Treatment of drug-induced psychosis in Parkinson's disease with ziprasidone can induce severe dose-dependent off- periods and pathological laughing. Clin Neurol Neurosurg 2007;109:188-191.PubMed Schindehutte J, Trenkwalder C. Treatment of drug-induced psychosis in Parkinson's disease with ziprasidone can induce severe dose-dependent off- periods and pathological laughing. Clin Neurol Neurosurg 2007;109:188-191.PubMed
68.
Zurück zum Zitat Friedman JH. Atypical antipsychotic drugs in the treatment of Parkinson's disease. J Pharm Pract 2011;24:534-540.PubMed Friedman JH. Atypical antipsychotic drugs in the treatment of Parkinson's disease. J Pharm Pract 2011;24:534-540.PubMed
69.
Zurück zum Zitat Friedman JH, Berman RM, Goetz CG, et al. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. Mov Disord 2006;21:2078-2081.PubMed Friedman JH, Berman RM, Goetz CG, et al. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. Mov Disord 2006;21:2078-2081.PubMed
70.
Zurück zum Zitat Factor SA, Friedman JH, Lannon MC, Oakes D, Bourgeois K, Parkinson SG. Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: results of the 12 week open label extension in the PSYCLOPS trial. Mov Disord 2001;16:135-139.PubMed Factor SA, Friedman JH, Lannon MC, Oakes D, Bourgeois K, Parkinson SG. Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: results of the 12 week open label extension in the PSYCLOPS trial. Mov Disord 2001;16:135-139.PubMed
71.
Zurück zum Zitat Pollak P, Tison F, Rascol O, et al. Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 2004;75:689-695.PubMed Pollak P, Tison F, Rascol O, et al. Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 2004;75:689-695.PubMed
72.
Zurück zum Zitat Ondo WG, Tintner R, Voung KD, Lai D, Ringholz G. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov Disord 2005;20:958-963.PubMed Ondo WG, Tintner R, Voung KD, Lai D, Ringholz G. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov Disord 2005;20:958-963.PubMed
73.
Zurück zum Zitat Rabey JM, Prokhorov T, Miniovitz A, Dobronevsky E, Klein C. Effect of quetiapine a double-blind in psychotic Parkinson's disease patients: labeled study of 3 months' duration. Mov Disord 2007;22:313-318.PubMed Rabey JM, Prokhorov T, Miniovitz A, Dobronevsky E, Klein C. Effect of quetiapine a double-blind in psychotic Parkinson's disease patients: labeled study of 3 months' duration. Mov Disord 2007;22:313-318.PubMed
74.
Zurück zum Zitat Fernandez HH, Okun MS, Rodriguez RL, et al. Quetiapine improves visual hallucinations in Parkinson disease but not through normalization of sleep architecture: results from a double-blind clinical-polysomnography study. Int J Neurosci 2009;119:2196-2205.PubMed Fernandez HH, Okun MS, Rodriguez RL, et al. Quetiapine improves visual hallucinations in Parkinson disease but not through normalization of sleep architecture: results from a double-blind clinical-polysomnography study. Int J Neurosci 2009;119:2196-2205.PubMed
75.
Zurück zum Zitat Morgante L, Epifanio A, Spina E, et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol 2004;27:153-156.PubMed Morgante L, Epifanio A, Spina E, et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol 2004;27:153-156.PubMed
76.
Zurück zum Zitat Merims D, Balas M, Peretz C, Shabtai H, Giladi N. Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis. Clin Neuropharmacol 2006;29:331-337.PubMed Merims D, Balas M, Peretz C, Shabtai H, Giladi N. Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis. Clin Neuropharmacol 2006;29:331-337.PubMed
77.
Zurück zum Zitat Meltzer HY, Mills R, Revell S, et al. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis. Neuropsychopharmacology 2010;35:881-892.PubMed Meltzer HY, Mills R, Revell S, et al. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis. Neuropsychopharmacology 2010;35:881-892.PubMed
78.
Zurück zum Zitat Cummings J, Isaacson S, Mills R, et al. Antipsychotic efficacy and motor tolerability in a phase III placebo-controlled study of pimavanserin in patients with Parkinson's disease psychosis (ACP-103-020). Mov Disord 2013;28:S170. Cummings J, Isaacson S, Mills R, et al. Antipsychotic efficacy and motor tolerability in a phase III placebo-controlled study of pimavanserin in patients with Parkinson's disease psychosis (ACP-103-020). Mov Disord 2013;28:S170.
79.
Zurück zum Zitat Burn D, Emre M, McKeith I, et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov Disord 2006;21:1899-1907.PubMed Burn D, Emre M, McKeith I, et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov Disord 2006;21:1899-1907.PubMed
80.
Zurück zum Zitat Postuma RB, Aarsland D, Barone P, et al. Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's disease. Mov Disord 2012;27:617-626.PubMed Postuma RB, Aarsland D, Barone P, et al. Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's disease. Mov Disord 2012;27:617-626.PubMed
81.
Zurück zum Zitat Lim SY, Fox SH, Lang AE. Overview of the extranigral aspects of Parkinson disease. Arch Neurol 2009;66:167-172.PubMed Lim SY, Fox SH, Lang AE. Overview of the extranigral aspects of Parkinson disease. Arch Neurol 2009;66:167-172.PubMed
82.
Zurück zum Zitat Factor SA, Molho ES. Emergency department presentations of patients with Parkinson's disease. Am J Emerg Med 2000;18:209-215.PubMed Factor SA, Molho ES. Emergency department presentations of patients with Parkinson's disease. Am J Emerg Med 2000;18:209-215.PubMed
83.
Zurück zum Zitat Hughes TA, Ross HF, Mindham RH, Spokes EG. Mortality in Parkinson's disease and its association with dementia and depression. Acta Neurol Scand 2004;110:118-123.PubMed Hughes TA, Ross HF, Mindham RH, Spokes EG. Mortality in Parkinson's disease and its association with dementia and depression. Acta Neurol Scand 2004;110:118-123.PubMed
84.
Zurück zum Zitat Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson's disease? J Neurol Neurosurg Psychiatry 2000;69:308-312.PubMed Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson's disease? J Neurol Neurosurg Psychiatry 2000;69:308-312.PubMed
85.
Zurück zum Zitat Hurt CS, Weinman J, Lee R, Brown RG. The relationship of depression and disease stage to patient perceptions of Parkinson's disease. J Health Psychol 2012;17:1076-1088.PubMed Hurt CS, Weinman J, Lee R, Brown RG. The relationship of depression and disease stage to patient perceptions of Parkinson's disease. J Health Psychol 2012;17:1076-1088.PubMed
86.
Zurück zum Zitat Santangelo G, Vitale C, Trojano L, et al. Relationship between depression and cognitive dysfunctions in Parkinson's disease without dementia. J Neurol 2009;256:632-638.PubMed Santangelo G, Vitale C, Trojano L, et al. Relationship between depression and cognitive dysfunctions in Parkinson's disease without dementia. J Neurol 2009;256:632-638.PubMed
87.
Zurück zum Zitat Ravina B, Camicioli R, Como PG, et al. The impact of depressive symptoms in early Parkinson disease. Neurology 2007;69:342-347.PubMedCentralPubMed Ravina B, Camicioli R, Como PG, et al. The impact of depressive symptoms in early Parkinson disease. Neurology 2007;69:342-347.PubMedCentralPubMed
88.
Zurück zum Zitat Leiknes I, Tysnes OB, Aarsland D, Larsen JP. Caregiver distress associated with neuropsychiatric problems in patients with early Parkinson's disease: the Norwegian ParkWest study. Acta Neurol Scand 2010;122:418-424.PubMed Leiknes I, Tysnes OB, Aarsland D, Larsen JP. Caregiver distress associated with neuropsychiatric problems in patients with early Parkinson's disease: the Norwegian ParkWest study. Acta Neurol Scand 2010;122:418-424.PubMed
89.
Zurück zum Zitat Seppi K, Weintraub D, Coelho M, et al. The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease. Mov Disord 2011;26:S42-S80.PubMed Seppi K, Weintraub D, Coelho M, et al. The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease. Mov Disord 2011;26:S42-S80.PubMed
90.
Zurück zum Zitat Tan LC. Mood disorders in Parkinson's disease. Parkinsonism Relat Disord 2012;18:S74-S76.PubMed Tan LC. Mood disorders in Parkinson's disease. Parkinsonism Relat Disord 2012;18:S74-S76.PubMed
91.
Zurück zum Zitat Reijnders JSAM, Ehrt U, Weber WEJ, Aarsland D, Leentjens AFG. A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord 2008;23:183-189.PubMed Reijnders JSAM, Ehrt U, Weber WEJ, Aarsland D, Leentjens AFG. A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord 2008;23:183-189.PubMed
92.
Zurück zum Zitat Ehrt U, Bronnick K, Leentjens AF, Larsen JP, Aarsland D. Depressive symptom profile in Parkinson's disease: a comparison with depression in elderly patients without Parkinson's disease. Int J Geriatr Psychiatry 2006;21:252-258.PubMed Ehrt U, Bronnick K, Leentjens AF, Larsen JP, Aarsland D. Depressive symptom profile in Parkinson's disease: a comparison with depression in elderly patients without Parkinson's disease. Int J Geriatr Psychiatry 2006;21:252-258.PubMed
93.
Zurück zum Zitat van der Hoek TC, Bus BA, Matui P, van der Marck MA, Esselink RA, Tendolkar I. Prevalence of depression in Parkinson's disease: effects of disease stage, motor subtype and gender. J Neurol Sci 2011;310:220-224.PubMed van der Hoek TC, Bus BA, Matui P, van der Marck MA, Esselink RA, Tendolkar I. Prevalence of depression in Parkinson's disease: effects of disease stage, motor subtype and gender. J Neurol Sci 2011;310:220-224.PubMed
94.
Zurück zum Zitat Aarsland D, Pahlhagen S, Ballard CG, Ehrt U, Svenningsson P. Depression in Parkinson disease--epidemiology, mechanisms and management. Nat Rev Neurol 2012;8:35-47. Aarsland D, Pahlhagen S, Ballard CG, Ehrt U, Svenningsson P. Depression in Parkinson disease--epidemiology, mechanisms and management. Nat Rev Neurol 2012;8:35-47.
95.
Zurück zum Zitat Storch A, Schneider CB, Wolz M, et al. Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications. Neurology 2013;80:800-809.PubMed Storch A, Schneider CB, Wolz M, et al. Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications. Neurology 2013;80:800-809.PubMed
96.
Zurück zum Zitat Rektorova I, Rektor I, Bares M, et al. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study. Eur J Neurol 2003;10:399-406.PubMed Rektorova I, Rektor I, Bares M, et al. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study. Eur J Neurol 2003;10:399-406.PubMed
97.
Zurück zum Zitat Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double- blind, placebo-controlled trial. Lancet Neurol 2010;9:573-580.PubMed Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double- blind, placebo-controlled trial. Lancet Neurol 2010;9:573-580.PubMed
98.
Zurück zum Zitat Barone P, Scarzella L, Marconi R, et al. Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study. J Neurol 2006;253:601-607.PubMed Barone P, Scarzella L, Marconi R, et al. Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study. J Neurol 2006;253:601-607.PubMed
99.
Zurück zum Zitat Leentjens AF. The role of dopamine agonists in the treatment of depression in patients with Parkinson's disease: a systematic review. Drugs 2011;71:273-286.PubMed Leentjens AF. The role of dopamine agonists in the treatment of depression in patients with Parkinson's disease: a systematic review. Drugs 2011;71:273-286.PubMed
100.
Zurück zum Zitat Ray CK, Martinez-Martin P, Antonini A, et al. Rotigotine and specific non-motor symptoms of Parkinson's disease: post hoc analysis of RECOVER. Parkinsonism Relat Disord 2013;19:660-665. Ray CK, Martinez-Martin P, Antonini A, et al. Rotigotine and specific non-motor symptoms of Parkinson's disease: post hoc analysis of RECOVER. Parkinsonism Relat Disord 2013;19:660-665.
101.
Zurück zum Zitat Rocha FL, Murad MG, Stumpf BP, Hara C, Fuzikawa C. Antidepressants for depression in Parkinson's disease: systematic review and meta-analysis. J Psychopharmacol 2013;27:417-423.PubMed Rocha FL, Murad MG, Stumpf BP, Hara C, Fuzikawa C. Antidepressants for depression in Parkinson's disease: systematic review and meta-analysis. J Psychopharmacol 2013;27:417-423.PubMed
102.
Zurück zum Zitat Akca A, Mehmet AK, Sutcugil L, et al. Comparison of sertraline and venlafaxine treatments for depression in Parkinson's disease. Noropsikiyatri Arsivi 2011;48:201-206. Akca A, Mehmet AK, Sutcugil L, et al. Comparison of sertraline and venlafaxine treatments for depression in Parkinson's disease. Noropsikiyatri Arsivi 2011;48:201-206.
103.
Zurück zum Zitat Richard IH, McDermott MP, Kurlan R, et al. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology 2012;78:1229-1236.PubMed Richard IH, McDermott MP, Kurlan R, et al. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology 2012;78:1229-1236.PubMed
104.
Zurück zum Zitat Menza M, Dobkin RD, Marin H, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 2009;72:886-892.PubMed Menza M, Dobkin RD, Marin H, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 2009;72:886-892.PubMed
105.
Zurück zum Zitat Wermuth L, Sorensen PS, Timm S, et al. Depression in idiopathic Parkinson's disease treated with citalopram: A placebo-controlled trial. XXX;1998:163-169. Wermuth L, Sorensen PS, Timm S, et al. Depression in idiopathic Parkinson's disease treated with citalopram: A placebo-controlled trial. XXX;1998:163-169.
106.
Zurück zum Zitat Leentjens AF, Vreeling FW, Luijckx GJ, Verhey FR. SSRIs in the treatment of depression in Parkinson's disease. Int J Geriatr Psychiatry 2003;18:552-554.PubMed Leentjens AF, Vreeling FW, Luijckx GJ, Verhey FR. SSRIs in the treatment of depression in Parkinson's disease. Int J Geriatr Psychiatry 2003;18:552-554.PubMed
107.
Zurück zum Zitat Devos D, Dujardin K, Poirot I, et al. Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord 2008;23:850-857.PubMed Devos D, Dujardin K, Poirot I, et al. Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord 2008;23:850-857.PubMed
108.
Zurück zum Zitat Skapinakis P, Bakola E, Salanti G, Lewis G, Kyritsis AP, Mavreas V. Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials - art. no. 49. BMC Neurol 2010;10:49.PubMedCentralPubMed Skapinakis P, Bakola E, Salanti G, Lewis G, Kyritsis AP, Mavreas V. Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials - art. no. 49. BMC Neurol 2010;10:49.PubMedCentralPubMed
109.
Zurück zum Zitat Ghaemi SN. Monoamine oxidase inhibitors and tricyclic antidepressants. Mood disorders: a practical guide. Philadelphia, PA: Wolters Kluwer Health/Lippincott Williams & Wilkins, 2008. Ghaemi SN. Monoamine oxidase inhibitors and tricyclic antidepressants. Mood disorders: a practical guide. Philadelphia, PA: Wolters Kluwer Health/Lippincott Williams & Wilkins, 2008.
110.
Zurück zum Zitat Weiser R, Hernandez-Rojas J, Flores J, et al. Efficacy, tolerability, and safety of mirtazapine in the treatment of major depressive disorder due to Parkinson's disease. Mov Disord 2004;19:S205. Weiser R, Hernandez-Rojas J, Flores J, et al. Efficacy, tolerability, and safety of mirtazapine in the treatment of major depressive disorder due to Parkinson's disease. Mov Disord 2004;19:S205.
111.
Zurück zum Zitat Zaluska M, Dyduch A. Bupropion in the treatment of depression in Parkinson's disease. Int Psychogeriatr 2011;23:325-327.PubMed Zaluska M, Dyduch A. Bupropion in the treatment of depression in Parkinson's disease. Int Psychogeriatr 2011;23:325-327.PubMed
112.
Zurück zum Zitat Raskin S, Durst R. Bupropion as the treatment of choice in depression associated with Parkinson's disease and it's various treatments. Med Hypotheses 2010;75:544-546.PubMed Raskin S, Durst R. Bupropion as the treatment of choice in depression associated with Parkinson's disease and it's various treatments. Med Hypotheses 2010;75:544-546.PubMed
113.
Zurück zum Zitat Lemke MR. Effect of reboxetine on depression in Parkinson's disease patients. J Clin Psychiatry 2002;63:300-304.PubMed Lemke MR. Effect of reboxetine on depression in Parkinson's disease patients. J Clin Psychiatry 2002;63:300-304.PubMed
114.
Zurück zum Zitat Richard IH, Kurlan R, Tanner C, et al. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Neurology 1997;48:1070-1077.PubMed Richard IH, Kurlan R, Tanner C, et al. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Neurology 1997;48:1070-1077.PubMed
115.
Zurück zum Zitat Ondo WG, Shinawi L, Davidson A, Lai D. Memantine for non-motor features of Parkinson's disease: a double-blind placebo controlled exploratory pilot trial. Parkinsonism Relat Disord 2011;17:156-159.PubMed Ondo WG, Shinawi L, Davidson A, Lai D. Memantine for non-motor features of Parkinson's disease: a double-blind placebo controlled exploratory pilot trial. Parkinsonism Relat Disord 2011;17:156-159.PubMed
116.
Zurück zum Zitat Secker DL, Brown RG. Cognitive behavioural therapy (CBT) for carers of patients with Parkinson's disease: a preliminary randomised controlled trial. J Neurol Neurosurg Psychiatry 2005;76:491-497.PubMed Secker DL, Brown RG. Cognitive behavioural therapy (CBT) for carers of patients with Parkinson's disease: a preliminary randomised controlled trial. J Neurol Neurosurg Psychiatry 2005;76:491-497.PubMed
117.
Zurück zum Zitat Dobkin RD, Menza M, Allen LA, et al. Cognitive-behavioral therapy for depression in Parkinson's disease: a randomized, controlled trial. Am J Psychiatry 2011;168:1066-1074.PubMedCentralPubMed Dobkin RD, Menza M, Allen LA, et al. Cognitive-behavioral therapy for depression in Parkinson's disease: a randomized, controlled trial. Am J Psychiatry 2011;168:1066-1074.PubMedCentralPubMed
118.
Zurück zum Zitat Dobkin RD, Menza M, Allen LA, et al. Telephone-based cognitive-behavioral therapy for depression in Parkinson disease. J Geriatr Psychiatry Neurol 2011;24:206-214.PubMedCentralPubMed Dobkin RD, Menza M, Allen LA, et al. Telephone-based cognitive-behavioral therapy for depression in Parkinson disease. J Geriatr Psychiatry Neurol 2011;24:206-214.PubMedCentralPubMed
119.
Zurück zum Zitat Holzer JC, Giakas WJ, Mazure CM, Price BH. Dysarthria during ECT given for Parkinson's disease and depression. Convuls Ther 1992;8:201-203.PubMed Holzer JC, Giakas WJ, Mazure CM, Price BH. Dysarthria during ECT given for Parkinson's disease and depression. Convuls Ther 1992;8:201-203.PubMed
120.
Zurück zum Zitat Friedman J, Gordon N. Electroconvulsive therapy in Parkinson's disease: a report on five cases. Convuls Ther 1992;8:204-210.PubMed Friedman J, Gordon N. Electroconvulsive therapy in Parkinson's disease: a report on five cases. Convuls Ther 1992;8:204-210.PubMed
121.
Zurück zum Zitat Bailine S, Kremen N, Kohen I, et al. Bitemporal electroconvulsive therapy for depression in a Parkinson disease patient with a deep-brain stimulator. J Ect 2008;24:171-172.PubMed Bailine S, Kremen N, Kohen I, et al. Bitemporal electroconvulsive therapy for depression in a Parkinson disease patient with a deep-brain stimulator. J Ect 2008;24:171-172.PubMed
122.
Zurück zum Zitat Dissanayaka NNW, Sellbach A, Matheson S, et al. Anxiety disorders in Parkinson's disease: prevalence and risk factors. Mov Disord 2010;25:838-845.PubMed Dissanayaka NNW, Sellbach A, Matheson S, et al. Anxiety disorders in Parkinson's disease: prevalence and risk factors. Mov Disord 2010;25:838-845.PubMed
123.
Zurück zum Zitat Factor SA. Literature review: intermittent subcutaneous apomorphine therapy in Parkinson's disease. Neurology 2004;62:S12-S17.PubMed Factor SA. Literature review: intermittent subcutaneous apomorphine therapy in Parkinson's disease. Neurology 2004;62:S12-S17.PubMed
124.
Zurück zum Zitat Baldwin D, Woods R, Lawson R, Taylor D. Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis. BMJ 2011;342:d1199.PubMed Baldwin D, Woods R, Lawson R, Taylor D. Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis. BMJ 2011;342:d1199.PubMed
125.
Zurück zum Zitat Santangelo G, Trojano L, Barone P, Errico D, Grossi D, Vitale C. Apathy in Parkinson's disease: diagnosis, neuropsychological correlates, pathophysiology and treatment. Behav Neurol 2013;27:501–513.PubMed Santangelo G, Trojano L, Barone P, Errico D, Grossi D, Vitale C. Apathy in Parkinson's disease: diagnosis, neuropsychological correlates, pathophysiology and treatment. Behav Neurol 2013;27:501–513.PubMed
126.
Zurück zum Zitat Butterfield LC, Cimino CR, Oelke LE, Hauser RA, Sanchez-Ramos J. The independent influence of apathy and depression on cognitive functioning in Parkinson's disease. Neuropsychology 2010;24:721-730.PubMed Butterfield LC, Cimino CR, Oelke LE, Hauser RA, Sanchez-Ramos J. The independent influence of apathy and depression on cognitive functioning in Parkinson's disease. Neuropsychology 2010;24:721-730.PubMed
127.
Zurück zum Zitat Barone P, Antonini A, Colosimo C, et al. The Priamo study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord 2009;24:1641-1649. Barone P, Antonini A, Colosimo C, et al. The Priamo study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord 2009;24:1641-1649.
128.
Zurück zum Zitat Dujardin K, Sockeel P, Delliaux M, Destee A, Defebvre L. Apathy may herald cognitive decline and dementia in Parkinson's disease. Mov Disord 2009;24:2391-2397.PubMed Dujardin K, Sockeel P, Delliaux M, Destee A, Defebvre L. Apathy may herald cognitive decline and dementia in Parkinson's disease. Mov Disord 2009;24:2391-2397.PubMed
129.
Zurück zum Zitat Harris E, McNamara P, Durso R. Apathy in patients with Parkinson disease as a function of side of onset. J Geriatr Psychiatry Neurol 2013;26:95-104.PubMed Harris E, McNamara P, Durso R. Apathy in patients with Parkinson disease as a function of side of onset. J Geriatr Psychiatry Neurol 2013;26:95-104.PubMed
130.
Zurück zum Zitat Kirsch-Darrow L, Zahodne LB, Marsiske M, Okun MS, Foote KD, Bowers D. The trajectory of apathy after deep brain stimulation: from pre-surgery to 6 months post-surgery in Parkinson's disease. Parkinsonism Relat Disord 2011;17:182-188.PubMedCentralPubMed Kirsch-Darrow L, Zahodne LB, Marsiske M, Okun MS, Foote KD, Bowers D. The trajectory of apathy after deep brain stimulation: from pre-surgery to 6 months post-surgery in Parkinson's disease. Parkinsonism Relat Disord 2011;17:182-188.PubMedCentralPubMed
131.
Zurück zum Zitat Czernecki V, Pillon B, Houeto JL, Pochon JB, Levy R, Dubois B. Motivation, reward, and Parkinson's disease: influence of dopatherapy. Neuropsychologia 2002;40:2257-2267.PubMed Czernecki V, Pillon B, Houeto JL, Pochon JB, Levy R, Dubois B. Motivation, reward, and Parkinson's disease: influence of dopatherapy. Neuropsychologia 2002;40:2257-2267.PubMed
132.
Zurück zum Zitat Czernecki V, Schupbach M, Yaici S, et al. Apathy following subthalamic stimulation in Parkinson disease: a dopamine responsive symptom. Mov Disord 2008;23:964-969.PubMed Czernecki V, Schupbach M, Yaici S, et al. Apathy following subthalamic stimulation in Parkinson disease: a dopamine responsive symptom. Mov Disord 2008;23:964-969.PubMed
133.
Zurück zum Zitat Evans AH, Strafella AP, Weintraub D, Stacy M. Impulsive and compulsive behaviors in Parkinson's disease. Mov Disord 2009;24:1561-1570.PubMed Evans AH, Strafella AP, Weintraub D, Stacy M. Impulsive and compulsive behaviors in Parkinson's disease. Mov Disord 2009;24:1561-1570.PubMed
134.
Zurück zum Zitat Mestre TA, Strafella AP, Thomsen T, Voon V, Miyasaki J. Diagnosis and treatment of impulse control disorders in patients with movement disorders. Ther Adv Neurol Disord 2013;6:175-188.PubMedCentralPubMed Mestre TA, Strafella AP, Thomsen T, Voon V, Miyasaki J. Diagnosis and treatment of impulse control disorders in patients with movement disorders. Ther Adv Neurol Disord 2013;6:175-188.PubMedCentralPubMed
135.
Zurück zum Zitat Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease a cross- sectional study of 3090 patients. Arch Neurol 2010;67:589-595.PubMed Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease a cross- sectional study of 3090 patients. Arch Neurol 2010;67:589-595.PubMed
136.
Zurück zum Zitat Perez-Lloret S, Rey MV, Fabre N, et al. Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with Parkinson disease. Clin Neuropharmacol 2012;35:261-265.PubMed Perez-Lloret S, Rey MV, Fabre N, et al. Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with Parkinson disease. Clin Neuropharmacol 2012;35:261-265.PubMed
137.
Zurück zum Zitat Ceravolo R, Frosini D, Rossi C, Bonuccelli U. Impulse control disorders in Parkinson's disease: definition, epidemiology, risk factors, neurobiology and management. Parkinsonism Relat Disord 2009;15:S111-S115.PubMed Ceravolo R, Frosini D, Rossi C, Bonuccelli U. Impulse control disorders in Parkinson's disease: definition, epidemiology, risk factors, neurobiology and management. Parkinsonism Relat Disord 2009;15:S111-S115.PubMed
138.
Zurück zum Zitat Weintraub D, Papay K, Siderowf A. Screening for impulse control symptoms in patients with de novo Parkinson disease: a case-control study. Neurology 2013;80:176-180.PubMed Weintraub D, Papay K, Siderowf A. Screening for impulse control symptoms in patients with de novo Parkinson disease: a case-control study. Neurology 2013;80:176-180.PubMed
139.
Zurück zum Zitat Poletti M, Logi C, Lucetti C, et al. A single-center, cross-sectional prevalence study of impulse control disorders in Parkinson disease: association with dopaminergic drugs. J Clin Psychopharmacol 2013;33:691–694.PubMed Poletti M, Logi C, Lucetti C, et al. A single-center, cross-sectional prevalence study of impulse control disorders in Parkinson disease: association with dopaminergic drugs. J Clin Psychopharmacol 2013;33:691–694.PubMed
140.
Zurück zum Zitat Rabinak CA, Nirenberg MJ. Dopamine Agonist withdrawal syndrome in Parkinson disease. Arch Neurol 2010;67:58-63.PubMed Rabinak CA, Nirenberg MJ. Dopamine Agonist withdrawal syndrome in Parkinson disease. Arch Neurol 2010;67:58-63.PubMed
141.
Zurück zum Zitat Pondal M, Marras C, Miyasaki J, et al. Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic. J Neurol Neurosurg Psychiatry 2013;84:130-135.PubMed Pondal M, Marras C, Miyasaki J, et al. Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic. J Neurol Neurosurg Psychiatry 2013;84:130-135.PubMed
142.
Zurück zum Zitat Thomas A, Bonanni L, Gambi F, Di IA, Onofrj M. Pathological gambling in Parkinson disease is reduced by amantadine. Ann Neurol 2010;68:400-404.PubMed Thomas A, Bonanni L, Gambi F, Di IA, Onofrj M. Pathological gambling in Parkinson disease is reduced by amantadine. Ann Neurol 2010;68:400-404.PubMed
143.
Zurück zum Zitat Weintraub D, Sohr M, Potenza MN, et al. Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Ann Neurol 2010;68:963-968.PubMed Weintraub D, Sohr M, Potenza MN, et al. Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Ann Neurol 2010;68:963-968.PubMed
144.
Zurück zum Zitat Bermejo PE, RuizHuete C, Anciones B. Zonisamide in managing impulse control disorders in Parkinson's disease. J Neurol 2010;257:1682-1685.PubMed Bermejo PE, RuizHuete C, Anciones B. Zonisamide in managing impulse control disorders in Parkinson's disease. J Neurol 2010;257:1682-1685.PubMed
145.
Zurück zum Zitat Ivanco LS, Bohnen NI. Effects of donepezil on compulsive hypersexual behavior in Parkinson disease: a single case study. Am J Ther 2005;12:467-468.PubMed Ivanco LS, Bohnen NI. Effects of donepezil on compulsive hypersexual behavior in Parkinson disease: a single case study. Am J Ther 2005;12:467-468.PubMed
146.
Zurück zum Zitat Sevincok L, Akoglu A, Akyol A. Quetiapine in a case with Parkinson disease and pathological gambling. J Clin Psychopharmacol 2007;27:107-108.PubMed Sevincok L, Akoglu A, Akyol A. Quetiapine in a case with Parkinson disease and pathological gambling. J Clin Psychopharmacol 2007;27:107-108.PubMed
147.
Zurück zum Zitat Rotondo A, Bosco D, Plastino M, Consoli A, Bosco F. Clozapine for medication-related pathological gambling in Parkinson disease. Mov Disord 2010;25:1994-1995.PubMed Rotondo A, Bosco D, Plastino M, Consoli A, Bosco F. Clozapine for medication-related pathological gambling in Parkinson disease. Mov Disord 2010;25:1994-1995.PubMed
148.
Zurück zum Zitat Trosch RM, Friedman JH, Lannon MC, et al. Clozapine use in Parkinson's disease: a retrospective analysis of a large multicentered clinical experience. Mov Disord 1998;13:377-382.PubMed Trosch RM, Friedman JH, Lannon MC, et al. Clozapine use in Parkinson's disease: a retrospective analysis of a large multicentered clinical experience. Mov Disord 1998;13:377-382.PubMed
149.
Zurück zum Zitat Klos KJ, Bower JH, Josephs KA, Matsumoto JY, Ahlskog JE. Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy. Parkinsonism Relat Disord 2005;11:381-386.PubMed Klos KJ, Bower JH, Josephs KA, Matsumoto JY, Ahlskog JE. Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy. Parkinsonism Relat Disord 2005;11:381-386.PubMed
150.
Zurück zum Zitat Bermejo PE. Topiramate in managing impulse control disorders in Parkinson's disease. Parkinsonism Relat Disord 2008;14:448-449.PubMed Bermejo PE. Topiramate in managing impulse control disorders in Parkinson's disease. Parkinsonism Relat Disord 2008;14:448-449.PubMed
151.
Zurück zum Zitat Bosco D, Plastino M, Colica C, et al. Opioid antagonist naltrexone for the treatment of pathological gambling in Parkinson disease. Clin Neuropharmacol 2012;35:118-120.PubMed Bosco D, Plastino M, Colica C, et al. Opioid antagonist naltrexone for the treatment of pathological gambling in Parkinson disease. Clin Neuropharmacol 2012;35:118-120.PubMed
152.
Zurück zum Zitat Bortolato M, Cannas A, Solla P, Bini V, Puligheddu M, Marrosu F. Finasteride attenuates pathological gambling in patients with Parkinson disease. J Clin Psychopharmacol 2012;32:424-425.PubMed Bortolato M, Cannas A, Solla P, Bini V, Puligheddu M, Marrosu F. Finasteride attenuates pathological gambling in patients with Parkinson disease. J Clin Psychopharmacol 2012;32:424-425.PubMed
153.
Zurück zum Zitat Haussermann P, Goecker D, Beier K, Schroeder S. Low-dose cyproterone acetate treatment of sexual acting out in men with dementia. Int Psychogeriatr 2003;15:181-186.PubMed Haussermann P, Goecker D, Beier K, Schroeder S. Low-dose cyproterone acetate treatment of sexual acting out in men with dementia. Int Psychogeriatr 2003;15:181-186.PubMed
154.
Zurück zum Zitat Mamikonyan E, Siderowf AD, Duda JE, et al. Long-term follow-up of impulse control disorders in Parkinson's disease. Mov Disord 2008;23:75-80.PubMedCentralPubMed Mamikonyan E, Siderowf AD, Duda JE, et al. Long-term follow-up of impulse control disorders in Parkinson's disease. Mov Disord 2008;23:75-80.PubMedCentralPubMed
155.
Zurück zum Zitat Kurlan R. Disabling repetitive behaviors in Parkinson's disease. Mov Disord 2004;19:433-437.PubMed Kurlan R. Disabling repetitive behaviors in Parkinson's disease. Mov Disord 2004;19:433-437.PubMed
156.
Zurück zum Zitat Gschwandtner U, Aston J, Renaud S, Fuhr P. Pathologic gambling in patients with Parkinson's disease. Clin Neuropharmacol 2001;24:170-172.PubMed Gschwandtner U, Aston J, Renaud S, Fuhr P. Pathologic gambling in patients with Parkinson's disease. Clin Neuropharmacol 2001;24:170-172.PubMed
157.
Zurück zum Zitat Seedat S, Kesler S, Niehaus DJ, Stein DJ. Pathological gambling behaviour: emergence secondary to treatment of Parkinson's disease with dopaminergic agents. Depress Anxiety 2000;11:185-186.PubMed Seedat S, Kesler S, Niehaus DJ, Stein DJ. Pathological gambling behaviour: emergence secondary to treatment of Parkinson's disease with dopaminergic agents. Depress Anxiety 2000;11:185-186.PubMed
158.
Zurück zum Zitat Weintraub D, Xie SX, Stern M, et al. Randomized, double-blind, placebo-controlled study of naltrexone for impulse control disorders in Parkinson's disease. Mov Disord 2013;28:S141. Weintraub D, Xie SX, Stern M, et al. Randomized, double-blind, placebo-controlled study of naltrexone for impulse control disorders in Parkinson's disease. Mov Disord 2013;28:S141.
159.
Zurück zum Zitat O'Sullivan SS, Evans AH, Lees AJ. Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management. CNS Drugs 2009;23:157-170.PubMed O'Sullivan SS, Evans AH, Lees AJ. Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management. CNS Drugs 2009;23:157-170.PubMed
160.
Zurück zum Zitat Evans AH, Lawrence AD, Potts J, Appel S, Lees AJ. Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease. Neurology 2005;65:1570-1574.PubMed Evans AH, Lawrence AD, Potts J, Appel S, Lees AJ. Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease. Neurology 2005;65:1570-1574.PubMed
161.
Zurück zum Zitat Giovannoni G, O'Sullivan JD, Turner K, Manson AJ, Lees AJL. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 2000;68:423-428.PubMed Giovannoni G, O'Sullivan JD, Turner K, Manson AJ, Lees AJL. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 2000;68:423-428.PubMed
162.
Zurück zum Zitat Sriram A, Ward HE, Hassan A, et al. Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinson's disease. J Neurol 2013;260:521-527.PubMed Sriram A, Ward HE, Hassan A, et al. Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinson's disease. J Neurol 2013;260:521-527.PubMed
163.
Zurück zum Zitat Lim SY, Evans AH, Miyasaki JM. Impulse control and related disorders in Parkinson's disease: review. Ann N Y Acad Sci 2008;1142:85-107.PubMed Lim SY, Evans AH, Miyasaki JM. Impulse control and related disorders in Parkinson's disease: review. Ann N Y Acad Sci 2008;1142:85-107.PubMed
164.
Zurück zum Zitat Kashihara K, Imamura T. Amantadine may reverse punding in Parkinson's disease - observation in a patient. Mov Disord 2008;23:129-130.PubMed Kashihara K, Imamura T. Amantadine may reverse punding in Parkinson's disease - observation in a patient. Mov Disord 2008;23:129-130.PubMed
165.
Zurück zum Zitat Hardwick A, Ward H, Hassan A, Romrell J, Okun MS. Clozapine as a potential treatment for refractory impulsive, compulsive, and punding behaviors in Parkinson's disease. Neurocase 2013;19:587–591.PubMed Hardwick A, Ward H, Hassan A, Romrell J, Okun MS. Clozapine as a potential treatment for refractory impulsive, compulsive, and punding behaviors in Parkinson's disease. Neurocase 2013;19:587–591.PubMed
166.
Zurück zum Zitat Evans AH, Katzenschlager R, Paviour D, et al. Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Mov Disord 2004;19:397-405.PubMed Evans AH, Katzenschlager R, Paviour D, et al. Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Mov Disord 2004;19:397-405.PubMed
167.
Zurück zum Zitat Fasano A, Ricciardi L, Pettorruso M, Bentivoglio AR. Management of punding in Parkinson's disease: an open-label prospective study. J Neurol 2011;258:656-660.PubMed Fasano A, Ricciardi L, Pettorruso M, Bentivoglio AR. Management of punding in Parkinson's disease: an open-label prospective study. J Neurol 2011;258:656-660.PubMed
168.
Zurück zum Zitat Okai D, Askey-Jones S, Samuel M, et al. Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers. Neurology 2013;80:792-799.PubMed Okai D, Askey-Jones S, Samuel M, et al. Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers. Neurology 2013;80:792-799.PubMed
169.
Zurück zum Zitat Ardouin C, Voon V, Worbe Y, et al. Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. Mov Disord 2006;21:1941-1946.PubMed Ardouin C, Voon V, Worbe Y, et al. Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. Mov Disord 2006;21:1941-1946.PubMed
170.
Zurück zum Zitat Eusebio A, Witjas T, Cohen J, et al. Subthalamic nucleus stimulation and compulsive use of dopaminergic medication in Parkinson's disease. J Neurol Neurosurg Psychiatry 2013;84:868–874.PubMed Eusebio A, Witjas T, Cohen J, et al. Subthalamic nucleus stimulation and compulsive use of dopaminergic medication in Parkinson's disease. J Neurol Neurosurg Psychiatry 2013;84:868–874.PubMed
171.
Zurück zum Zitat Smeding HMM, Goudriaan AE, Foncke EMJ, Schuurman PR, Speelman JD, Schmand B. Pathological gambling after bilateral subthalamic nucleus stimulation in Parkinson disease. J Neurol Neurosurg Psychiatry 2007;78:517-519.PubMed Smeding HMM, Goudriaan AE, Foncke EMJ, Schuurman PR, Speelman JD, Schmand B. Pathological gambling after bilateral subthalamic nucleus stimulation in Parkinson disease. J Neurol Neurosurg Psychiatry 2007;78:517-519.PubMed
172.
Zurück zum Zitat Lim SY, O'Sullivan SS, Kotschet K, et al. Dopamine dysregulation syndrome, impulse control disorders and punding after deep brain stimulation surgery for Parkinson's disease. J Clin Neurosci 2009;16:1148-1152.PubMed Lim SY, O'Sullivan SS, Kotschet K, et al. Dopamine dysregulation syndrome, impulse control disorders and punding after deep brain stimulation surgery for Parkinson's disease. J Clin Neurosci 2009;16:1148-1152.PubMed
173.
Zurück zum Zitat Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. The Parkinson Study Group. N Engl J Med 1999;340:757-763. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. The Parkinson Study Group. N Engl J Med 1999;340:757-763.
174.
Zurück zum Zitat Clozapine in drug-induced psychosis in Parkinson’s disease. The French Clozapine Parkinson Study Group. Lancet 1999;53:2041-2042. Clozapine in drug-induced psychosis in Parkinson’s disease. The French Clozapine Parkinson Study Group. Lancet 1999;53:2041-2042.
175.
Zurück zum Zitat Avila A, Cardona X, Martin-Baranera M, Maho P, Sastre F, Bello J. Does nefazodone improve both depression and Parkinson’s disease? A pilot randomized trial. J Clin Psychopharmacol 2003;23:509-513.PubMed Avila A, Cardona X, Martin-Baranera M, Maho P, Sastre F, Bello J. Does nefazodone improve both depression and Parkinson’s disease? A pilot randomized trial. J Clin Psychopharmacol 2003;23:509-513.PubMed
176.
Zurück zum Zitat Antonini A, Tesei S, Zecchinelli A, et al. Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson’s disease and depression: effect on quality of life. Mov Disord 2006;21:1119-1122.PubMed Antonini A, Tesei S, Zecchinelli A, et al. Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson’s disease and depression: effect on quality of life. Mov Disord 2006;21:1119-1122.PubMed
Metadaten
Titel
Treatment of Cognitive, Psychiatric, and Affective Disorders Associated with Parkinson’s Disease
verfasst von
Barbara Connolly
Susan H. Fox
Publikationsdatum
01.01.2014
Verlag
Springer US
Erschienen in
Neurotherapeutics / Ausgabe 1/2014
Print ISSN: 1933-7213
Elektronische ISSN: 1878-7479
DOI
https://doi.org/10.1007/s13311-013-0238-x

Weitere Artikel der Ausgabe 1/2014

Neurotherapeutics 1/2014 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.